ANEB
Anebulo Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.36
−8.05%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | — | — | — |
| Cost of Revenue | — | — | — | — | — |
| Gross Profit | — | — | — | — | — |
| Operating Expenses | |||||
| R&D Expense | 3.7M | 4.3M | 3.5M | 5.6M | 3.0M |
| SG&A Expense | 5.4M | 4.9M | 4.8M | 6.2M | 3.9M |
| General & Admin Expense | 2.9M | — | 4.8M | — | — |
| Selling & Marketing Expense | — | — | 4.8K | — | — |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 9.1M | 9.2M | 8.3M | 11.8M | 6.8M |
| Cost and Expenses | 9.1M | 9.2M | 8.3M | 11.8M | 6.8M |
| Operating Income (EBIT) | (9.1M) | (9.2M) | (8.3M) | (11.8M) | (6.8M) |
| Non-Operating | |||||
| Interest Income | 419.9K | 257.9K | 249.0K | 92.4K | 7.3K |
| Interest Expense | 297.5K | 382.0K | 151.2K | — | — |
| Net Interest Income | 122.4K | (124.1K) | 97.8K | 92.4K | 7.3K |
| Other Non-Op Income/Expense | 1.1M | 738.7K | 107.1K | 51.3K | 5.6K |
| Non-Operating Income (excl Interest) | (1.4M) | (1.1M) | (258.0K) | (51.3K) | (5.6K) |
| EBT (Pre-Tax Income) | (8.0M) | (8.5M) | (8.2M) | (11.7M) | (6.8M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (8.0M) | (8.5M) | (8.2M) | (11.7M) | (6.8M) |
| Earnings from Cont. Ops | (8.0M) | (8.5M) | (8.2M) | (11.7M) | (6.8M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (8.0M) | (8.5M) | (8.2M) | (11.7M) | (6.8M) |
| Per Share | |||||
| Basic EPS | ($0.19) | ($0.25) | ($0.32) | ($0.47) | ($0.29) |
| Diluted EPS | ($0.21) | ($0.25) | ($0.32) | ($0.47) | ($0.29) |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 41.1M | 33.8M | 25.8M | 25.1M | 23.3M |
| Diluted Shares Outstanding | 41.1M | 33.8M | 25.8M | 25.1M | 23.3M |
| Profitability Metrics | |||||
| EBITDA | (7.4M) | (7.7M) | (7.8M) | (11.7M) | (6.8M) |
| D&A | 262.6K | 382.0K | 258.3K | — | — |
| EBIT | (7.7M) | (8.1M) | (8.1M) | (11.7M) | (6.8M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Dec 1, 2025